NasdaqGS:ARWRBiotechs
Arrowhead Pharmaceuticals (ARWR) Valuation Check After Earnings Jump And S&P Index Move
Earnings jump and index reshuffle put Arrowhead in focus
Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting first quarter results that moved from a year-ago loss to profitability, alongside a shift from the S&P 600 to the S&P 400 indices.
See our latest analysis for Arrowhead Pharmaceuticals.
At a share price of US$63.82, Arrowhead has seen a 59% 90 day share price return and a very large 1 year total shareholder return of 220%, suggesting momentum has built around the...